Milestone Pharmaceuticals files US$300M shelf and US$100M ATM with Cantor Fitzgerald as agent

On May 13, 2026, Milestone Pharmaceuticals Inc. (“Milestone”) filed a registration statement for a shelf prospectus to offer up to US$300 million of securities, including common shares, preferred shares, debt securities and warrants. The filing includes a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. providing for the sale of up to US$100 million of common shares from time to time, with Cantor Fitzgerald & Co. ("Cantor") acting as agent.

Milestone, headquartered in Montréal, Québec, is a clinical-stage pharmaceutical company with a focus on the development of cardiovascular medicines.

McCarthy Tétrault LLP advised Cantor with a team led by Charles-Antoine Soulière and Andrew Parker that included Laurence Cromp-Lapierre.